Latest News
Recent Posts
T1.Done & Creators for Cures are back
Spring has sprung, and with it comes the return of two of our favorite fundraisers.
Talking with Dr Yuan Gao, recipient of our career support and travel grant
Hear from one of our latest travel grant recipients, Dr Yuan Gao, about her experience attending the IDS Congress in
T1.Done Returns April 26–27
See the lineup for our second annual speedrunning fundraiser, hosted by Spikevegeta.
Register for Creators for Cures on Tiltify
Our celebration of our community’s creativity is back May 11–18.
Changing gut flora could help delay type 1 diabetes
Breakthrough T1D-funded research has found that products released by the gut microbiome could play a role in slowing down the
Making medical research programmes and clinical trials more accessible and inclusive
Read our top takeaways from the “Recruiting to medical research programmes and trials — how can we be smarter and
Novo Nordisk to discontinue Levemir insulin by end of 2026
Novo Nordisk will stop producing Levemir insulin next year but there are plans in place to help you transition to
See who’s streaming during the Game Over, T1D! Steam sale
Our community streamers can help you decide which games to buy in the sale.
Save big in the Game Over, T1D! Steam Sale
More than 50 games, up to 85% off! The sale runs February 13–20 on Steam.
Follow for more updates:
EVERYONE! We have a matching donation going on for our charity event to fight type 1 diabetes. If you want to have your donation matched, click here:
https://donate.tiltify.com/b0fb1df3-5ce4-49c9-97a2-4ebb813012d6/incentives
#t1d @BT1D_Play #charity
We're going live with Nick Herman and Dennis Lenart from @adhocstudio.com to play Dispatch! Come hang with us and maybe win a Steam key!
👾DEV DIARIES👾
Join us next week for an exclusive look at @theAdHocStudio's new game: Dispatch! 🦸
AdHoc Studio's cofounders, @ItsMeNickHerman and @dennis_lenart, will join us as we play through Dispatch. Come check out the game & learn more about its creation!
🗓️ Thurs, Nov.…
Follow for more updates:
